IP Library Granted Patent US 8,106,024
Granted Patent B2
US 8,106,024 · App. 12/304,888 · Granted Jan 31, 2012

Method of treating cancer with an RPN2 gene expression inhibitor

Assignees: Taisho Pharmaceutical Co., Ltd.; Dainippon Sumitomo Pharma Co., Ltd.; Japan as represented by President of National Cancer Center; Koken Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,106,024
App. No.
12/304,888
Granted
Jan 31, 2012
Kind
B2
Abstract

The present invention uses an RPN2 gene expression inhibitor as a cancer cell growth inhibitor, which further includes a drug showing an anti-cancer action if desired, and is administered in combination with atelocollagen if desired. In addition, the present invention is an anti-cancer agent including such cancer cell growth inhibitor.

Claims (10)

1. A method of treating cancer comprising administering to a patient in need thereof a ribophorin II (RPN2) gene expression inhibitor as an anti-cancer agent, wherein the RPN2 gene expression inhibitor is an RPN2-targeted siRNA that suppresses RPN2 gene expression by RNA interference, wherein the cancer being treated is one that is responsive to the RPN2 gene expression inhibitor that is administered, and wherein the administration results in an anti-cancer effect.

2. A method of treating cancer comprising administering to a patient in need thereof an RPN2 gene expression inhibitor as an anti-cancer agent in combination with a drug showing an anti-cancer action, wherein the cancer being treated is one that is responsive to the RPN2 gene expression inhibitor that is administered, and wherein the administration results in an anti-cancer effect.

3. The method of treating cancer as set forth in claim 1 , wherein the RPN2 gene expression inhibitor is administered in combination with atelocollagen.

4. The method of treating cancer as set forth in claim 2 , wherein the RPN2 gene expression inhibitor is administered in combination with atelocollagen.

5. The method of treating cancer as set forth in claim 2 , wherein said drug showing an anti-cancer action is a taxane.

6. The method of treating cancer as set forth in claim 2 , wherein said drug showing an anti-cancer action is a platinum-based chemotherapy drug.

7. The method of treating cancer as set forth in claim 1 , wherein the cancer is selected from the group consisting of breast cancer, lung cancer, liver cancer, and colon cancer.

8. The method of treating cancer as set forth in claim 1 , wherein the cancer is breast cancer.

9. The method of treating cancer as set forth in claim 1 , wherein the cancer is lung cancer.

10. The method of treating cancer as set forth in claim 2 , wherein the cancer is selected from the group consisting of breast cancer, lung cancer, liver cancer, and colon cancer.

Assignments (4)
CHANGE OF ADDRESS Recorded Jan 24, 2023
From: SUMITOMO PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 062475/0509 →
CHANGE OF NAME Recorded Jan 24, 2023
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 063753/0826 →
CHANGE OF NAME Recorded Nov 4, 2014
From: DAINIPPON SUMITOMO PHARMA CO., LTD.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 034160/0613 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2009
From: OCHIYA, TAKAHIRO; KATO, KIKUYA; HONMA, KIMI; UEDA, YASUJI
To: TAISHO PHARMACEUTICAL CO., LTD.; DAINIPPON SUMITOMO PHARMA CO., LTD.; JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CANCER CENTER; KOKEN CO., LTD.
Reel/Frame 022692/0384 →
Priority Claims (1)
JP 2006-167886 · Jun 16, 2006 · national
Continuity (1)
Related Publication 20100087507A1 · Apr 8, 2010